| Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. | |
| | |
MedLine Citation:
|
PMID: 1453204 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The goal of this study was to evaluate the toxicity of iodine 131 metaiodobenzylguanidine (mIBG) in metastatic neuroblastoma. PATIENTS AND METHODS: A multicenter phase I study of 131I mIBG has been undertaken by the United Kingdom Children's Cancer Study Group (UKCCSG) in children with advanced chemoresistant neuroblastoma. Activity prescription was based on a prescribed whole-body radiation dose, which was established for individual patients by performing an initial tracer investigation with 75 MBq of 131I mIBG. An activity was derived from this pharmacokinetic study that would deliver an initial whole-body-absorbed radiation dose of 1 Gy. Subsequent dose escalations were based on observed toxicity. RESULTS: Twenty-five patients, aged 1 to 10 years, were treated with prescribed whole-body dose levels of 1.0 Gy (n = 2), 2.0 Gy (n = 13), and 2.5 Gy (n = 10). This necessitated administration of 2.4 to 12.1 GBq of activity. Hematologic, hepatic, kidney, and adrenal toxicity were observed, with bone marrow suppression being the principal dose-limiting toxicity. Bone marrow toxicity increased with prescribed whole-body-absorbed radiation dose, with 80% of patients developing grade 3 or 4 thrombocytopenia at a prescribed whole-body radiation dose of 2.5 Gy. Objective evidence of tumor response was seen in soft tissue (primary or nodal disease), bone, and bone marrow, with an overall response rate of 33% (partial response, n = 8; static disease, n = 9; progressive disease, n = 7). CONCLUSIONS: This study has established an effective method of activity prescription that predicts subsequent toxicity, with the maximally tolerated dose being sufficient activity to deliver a whole-body-absorbed radiation dose of 2.5 Gy. The objective response rate is comparable to other single agents in chemoresistant neuroblastoma and suggests that 131I mIBG may be a useful method for targeting radiotherapy in metastatic neuroblastoma. |
| | |
Authors:
|
L S Lashford; I J Lewis; S L Fielding; M A Flower; S Meller; J T Kemshead; D Ackery |
Related Documents
:
|
8625194 - Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis. 11107134 - Prognostic significance of gage detection in bone marrows on survival of patients with ... 16941154 - Prognostic value of the international neuroblastoma pathology classification in neurobl... 9002754 - Treatment with meta-[131i]iodobenzylguanidine and cisplatin in stage iv neuroblastoma. 17197284 - Effects of photodynamic therapy using 5-aminolevulinic acid on cultured human adenomyos... 23436014 - Time-varying pattern of recurrence risk for gastric cancer patients. |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 10 ISSN: 0732-183X ISO Abbreviation: J. Clin. Oncol. Publication Date: 1992 Dec |
Date Detail:
|
Created Date: 1993-01-07 Completed Date: 1993-01-07 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1889-96 Citation Subset: IM |
Affiliation:
|
Department of Paediatric Oncology, St James's University Hospital, Leeds, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
3-Iodobenzylguanidine Child Child, Preschool Drug Resistance Humans Infant Iodine Radioisotopes / administration & dosage, therapeutic use* Iodobenzenes / adverse effects Neuroblastoma / radiotherapy* Radiotherapy Dosage Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Iodine Radioisotopes; 0/Iodobenzenes; 77679-27-7/3-Iodobenzylguanidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Residual disease at the end of induction therapy as a predictor of relapse during therapy in childho...
Next Document: Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metaboli...